Drug of Choice for Zygomycosis (Mucormycosis)
The correct answer is B) Amphotericin B—specifically, liposomal amphotericin B at 5-10 mg/kg per day is the strongly recommended first-line treatment for mucormycosis across all patterns of organ involvement 1.
Why Amphotericin B is the Drug of Choice
The 2019 global guideline from the European Confederation of Medical Mycology provides the highest quality evidence for this recommendation 1. First-line treatment with liposomal amphotericin B 5–10 mg/kg per day is strongly supported, with the full daily dose given from day 1—avoiding slow dose escalation which can compromise outcomes 1.
Key Treatment Principles:
- Immediate initiation: Mucormycosis is a medical emergency requiring rapid antifungal therapy without delay 1
- High-dose from start: Begin at 5-10 mg/kg/day immediately; do not escalate slowly 1
- CNS involvement: Use 10 mg/kg/day for central nervous system disease 1
- Non-CNS disease: Amphotericin B lipid complex 5 mg/kg/day is moderately recommended 1
Why the Other Options Are Incorrect
A) Fluconazole - Has NO activity against Mucorales and should never be used 2
C) Nystatin - Only for topical/mucosal candidiasis; no role in invasive mucormycosis
D) Voriconazole - Mucorales are intrinsically resistant to voriconazole. Importantly, voriconazole use has been associated with breakthrough mucormycosis in immunosuppressed patients 3, 4
E) Caspofungin - Echinocandins have no activity against Mucorales 3
Alternative First-Line Options
While amphotericin B remains the traditional drug of choice, the 2019 guidelines also provide moderate support for isavuconazole as first-line therapy (200 mg three times on day 1, then 200 mg daily from day 3) 1. Isavuconazole is FDA-approved for first-line mucormycosis treatment in the USA and offers advantages of less nephrotoxicity and hepatotoxicity compared to amphotericin B 1.
Posaconazole (IV or delayed-release tablets) receives moderate support for first-line use, though oral suspension has only marginal support due to bioavailability concerns 1.
Critical Clinical Caveats
- Renal toxicity management: If significant nephrotoxicity develops with amphotericin B, doses can be reduced, but doses below 5 mg/kg/day have only marginal support 1
- Amphotericin B deoxycholate: While historically the "drug of choice for decades," it should be restricted to settings where lipid formulations are unavailable due to substantial toxicity 1
- Surgical debridement: Antifungal therapy alone is insufficient—aggressive surgical debridement with clean margins is strongly recommended alongside medical therapy 1, 2
- Duration: Continue treatment until permanent reversal of immunosuppression and complete radiographic response, typically weeks to months 1
The answer is definitively B) Amphotericin B, with liposomal formulations preferred over conventional amphotericin B deoxycholate whenever available.